Healthcare Gainers: Gentiva Health Services (NASDAQ:GTIV), bluebird bio Inc (NASDAQ:BLUE), Celldex Therapeutics (NASDAQ:CLDX), Intercept Pharmaceuticals (NASDAQ:ICPT), Northwest Biotherapeutics (NASDAQ:NWBO)

Gentiva Health Services Inc. (NASDAQ:GTIV)’s rejection of the takeover proposal from Kindred Healthcare Inc. ( KND ) is hitting headlines and drawing investor attention to the healthcare space. Gentiva Health Services, Inc. (NASDAQ:GTIV) stock performance was -1.52% in last session and finished the day at $13.62. Traded volume was 1.47million shares in the last session and the average volume of the stock remained 471.48K shares. The beta of the stock remained 1.53. Gentiva Health Services, Inc. (NASDAQ:GTIV) insider ownership is 9.60%.

bluebird bio Inc (NASDAQ:BLUE) COO Jeffrey Walsh sold 4,500 shares of bluebird bio stock on the open market in a transaction dated Monday, May 12th. The stock was sold at an average price of $18.93, for a total value of $85,185.00. bluebird bio Inc (NASDAQ:BLUE) rose 2.69 percent to $25.18 Friday on volume of 272,285.00million shares. The intra-day range of the stock was $23.89 to $25.30. bluebird bio Inc (NASDAQ:BLUE) has a market capitalization of $617.21million.

Hampton, NJ-based Celldex Therapeutics, Inc (NASDAQ: CLDX) became the latest beneficiary of that strategy this week when it cut a deal with Bristol-Myers Squibb to run a trial Celldex Therapeutics, Inc (NASDAQ: CLDX)’s varlilumab in combination with Bristol-Myers’ nivolumab. The two companies will share the costs of a Phase 1/2 study testing the two drugs in a variety of cancers. Afterwards, should Celldex decide to license out its drug, Bristol-Myers will get an exclusive window to negotiate a deal. Celldex is also getting $5 million up front, and can waive future milestone payments and reduce royalty rates it would’ve owed to Medarex (now a subsidiary of Bristol-Myers). Celldex Therapeutics, Inc (NASDAQ: CLDX) shares jumped more than 24 percent on the news. Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s stock on May 16, 2014 reported a decrease of -4.92% to the closing price of $13.33. Its fifty two weeks range is $10.76 -$38.84. The total market capitalization recorded $1.19billion. The overall volume in the last trading session was 2.37million shares. In its share capital, CLDX has 89.35million outstanding shares.

When Intercept Pharmaceuticals Inc (NASDAQ:ICPT) announced early in January that its mid-stage FLINT trial of obethicholic acid (OCA) for non-alcoholic steatohepatitis (NASH) was stopped early because it had already hit its primary endpoint, the stock went parabolic, shooting from $72 to a high of $497 in less than two days. That’s a move of 590 percent for those keeping track. After a pullback and another run near that high, the stock has been halved to around $240 per share. On Friday, shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) dropped -0.66% to close the day at $280.26. Company return on investment (ROI) is -47.90% and its monthly performance is recorded as 18.00%. Intercept Pharmaceuticals Inc (NASDAQ:ICPT) quarterly revenue growth is -19.12%.

Northwest Biotherapeutics, Inc (NASDAQ:NWBO), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, recently provided an initial patient case study, showing signs of tumor necrosis (tumor death) and initial tumor regression, from the Company’s ongoing DCVax-Direct trial for all types of inoperable solid tumors. The Company plans to announce further case study information prior to the annual ASCO conference, while it continues collecting data from the trial. Although the trial is still at an early stage, with many of the patients only part way through the treatment regimen, the Company also plans to provide overall information about the data to date by the time of the ASCO conference. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) stock performance was -2.83% in last session and finished the day at $5.83. Traded volume was 888,525.00million shares in the last session and the average volume of the stock remained 1.22million shares. The beta of the stock remained 2.71. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) insider ownership is 9.86%.